|
Post by sportsrancho on Feb 8, 2019 20:34:53 GMT -5
Check my last post on StockTwits :-) Kelly Kraft
ST...$MNKD another long time MNKD Executive leaves to join Receptor in February 2019 Product Development is news coming linkedin.com/in/kelly-kraft... Kevinmik found it.
|
|
|
RLS
Feb 8, 2019 20:41:15 GMT -5
via mobile
Post by mango on Feb 8, 2019 20:41:15 GMT -5
Right, $1M I believe. Perhaps that one payment around the end of the other year to MNKD was $2M though. It was either $1M or $2M. It was not more than $2M I’m sure of. Relatively speaking, If it was $2M it may as well have been just $1M. I’ll stick with $1M Mango, these RLS oral doses; do you think the technology for them could have come from a MNKD patent or more? Would you know if Ms. Leon-Bay had ever helped patent oral technology dosaging for MNKD? MannKind has patents covering oral formulations and some have Andrea Leone-Bay listed as an inventor. I suspect RLS might not use MannKind's IP for oral formulations, but that's just speculation. RLS has SNAC and NAC (acid form of SNAC) in at least one patent of theirs. Those are carriers/absorption enhancers. SNAC was discovered by Emisphere and is GRAS by FDA. I think MannKind's IP is licensed just for inhaled products I think, but don't know 100% for sure. The manufacturing tech is also part of the deal, and RLS has the right to sublicense as well, which MannKind would receive royalties from any of those too. Speaking of GRAS...Beta-caryophyllene, Linalool, and Limonene are a few terpenes common to the Cannabis planet, but also abundant throughout nature. These are also labeled GRAS by FDA. Interestingly enough, beta-caryophyellene is a full CB2 receptor agonist, with a much higher binding affinity than THC. Beta-caryophellene is a common constituent of the essential oils of many herbs and spices found in nearly every household around the world. So we already have a dietary cannabinoid with the government's stamp of approval.
|
|
|
Post by mango on Feb 8, 2019 20:45:31 GMT -5
Check my last post on StockTwits :-) Kelly Kraft ST...$MNKD another long time MNKD Executive leaves to join Receptor in February 2019 Product Development is news coming linkedin.com/in/kelly-kraft... Kevinmik found it. From her LinkedIn Kelly Kraft Vice President, Product Development at Receptor Life Sciences
|
|
|
Post by brotherm1 on Feb 8, 2019 20:51:58 GMT -5
She is also listed as having been a scientist for the Emisphere company you mentioned above.
|
|
|
Post by mango on Feb 8, 2019 20:58:37 GMT -5
She is also listed as having been a scientist for the Emisphere company you mentioned above. Andrea Leone-Bay worked there too.
|
|
|
RLS
Feb 8, 2019 21:12:02 GMT -5
via mobile
Post by uvula on Feb 8, 2019 21:12:02 GMT -5
Is kevinmik still around? He was the yahoo doctor who was all over the place, right?
|
|
|
Post by nylefty on Feb 8, 2019 21:13:00 GMT -5
Kelly Kraft Vice President, Product Development at Receptor Life Sciences Danbury, Connecticut
Pharmaceutical professional, specializing in drug delivery, with extensive background in both research and development, and with medicinal chemistry, process chemistry, and formulations development experience. Proven manager with excellent inter-personal and team-building skills. Effectively adapts to rapidly changing priorities. Detail- and timeline-oriented.
Dates Employed Feb 2019 – Present Employment Duration 1 mo
MannKind Corporation Director, Pharmaceutical Research
Dates Employed Jun 2003 – Feb 2019
Employment Duration 15 yrs 9 mos
Held positions with increasing responsibility, from laboratory scientist to department director.
As Director of Pharmaceutical Research, responsibilities include identifying drug candidates and developing strategies for MannKind's inhalation drug delivery pipeline while simultaneously maintaining responsibility for chemical and formulation research on Afrezza (inhaled insulin) and its line extensions for product life cycle management.
Other notable responsibilities and accomplishments include:
• Establishing and leading a cross-functional team to execute a pipeline program from research stage through a successful first-in-man clinical trial
• Building and driving timelines for a US FDA IND submission
• Authoring and reviewing sections of regulatory documents for US FDA submissions (IND and NDA)
• Establishing, with Quality Assurance, a Phase 1 clinical manufacturing suite
• Directing work of up to six formulation, chemistry, and analytical scientists
• Developing and optimizing a new manufacturing process to lower novel excipient COGS by 40%
• Designing and synthesizing multi-gram quantities of novel delivery agent candidates
• Serving on and/or leading cross-disciplinary development program teams
Emisphere Technologies
Scientist Dates Employed Aug 1998 – Jun 2003 Employment Duration 4 yrs 11 mos
Laboratory scientist and manager in the process chemistry and medicinal chemistry departments.
Notable responsibilities and accomplishments included:
• Design and synthesis of small molecule drug delivery agents at 100 mg to 22-L scale
• Identifying and executing scaleable synthetic methodologies in standard and automated laboratory reactors
• Serving on and/or leading cross-disciplinary research and development program teams
• Authoring SOPs and IQ/OQs for the cGMP laboratory
Education
The University of Georgia
Degree Name PhD Field Of Study Medicinal Chemistry
Dates attended or expected graduation 1994 – 1998
Elizabethtown College
Degree Name BS Field Of Study Chemistry Dates attended or expected graduation 1990 – 1994
|
|
|
Post by theshiv on Feb 8, 2019 21:16:51 GMT -5
I find these moves simply fascinating. What was she told to make the move and what future announcements are pending?
|
|
|
Post by sportsrancho on Feb 8, 2019 21:51:20 GMT -5
I find these moves simply fascinating. What was she told to make the move and what future announcements are pending? You wouldn’t believe how many people have called me tonight, “fascinating” was is the main consensus :-))
|
|
|
Post by mango on Feb 8, 2019 22:10:58 GMT -5
I find these moves simply fascinating. What was she told to make the move and what future announcements are pending? The moves have been in the works for a while. • When does the agreement begin and what are the key milestones? The agreement is effective as of January 20, 2016. As is typical with development deals of this sort, up-front money is minimal, as such payments are reflective of the work already done by the licensor and the risks taken by the licensee. At this point, we have spent little and risked less in validating this possibility. Most of this work is still ahead of us. Even then, our costs are largely confined to supporting their efforts using existing personnel, so our incremental out of pocket costs are minimal. All the risk and virtually all the cost will borne by Receptor. As they proceed down the development path and achieve specific developmental goals, we receive milestone payments in recognition of the increasing value of our technology in their hands. Again, as is typical, the specific milestones and associated payments are not disclosed for competitive reasons, but I can say the first material milestone is expected to be received this year, if all goes according to plan. Total milestones that might be earned total over $100 million, but the real value of this license would come from royalties if successful. • What are MannKind’s responsibilities in the licensing agreement? MannKind is responsible for transferring necessary technical information about the Technosphere platform to the licensee and then providing ancillary support as they develop their product on the Technosphere platform, and ultimately ramp up their manufacturing capability. To support these efforts, MannKind will name a team of existing scientific and manufacturing personnel to work with a corresponding team from the licensee, and a project plan will be implemented to manage the process. We anticipate no incremental costs to MannKind, just the costs of existing personnel. www.mannkindcorp.com/Collateral/Documents/English-US/TS%20licensing%20FAQ.pdf
|
|
|
Post by theshiv on Feb 8, 2019 22:16:51 GMT -5
Sports, Yes you are! I feel that most professionals like Andrea and Ms. Kraft and others with heavy credentials don't make these career moves in a cavalier manner. These are strategic moves and they simply don't wake up and say, I think I'll start a new job today. There has to be something convincing for them to make the move.
|
|
|
Post by goyocafe on Feb 8, 2019 22:23:23 GMT -5
Sports, Yes you are! I feel that most professionals like Andrea and Ms. Kraft and others with heavy credentials don't make these career moves in a cavalier manner. These are strategic moves and they simply don't wake up and say, I think I'll start a new job today. There has to be something convincing for them to make the move. And as close as this cooperating agreement is, I highly doubt either company can pilfer talent from the other without consent.
|
|
|
Post by boca1girl on Feb 8, 2019 22:25:11 GMT -5
Does anyone know what the milestones are for the RLS agreement? It looks like it has been some time since it was announced. If I am not incorrect they have only paid $1M on a potential of $100M+ of cash milestones. Is this agreement structure different from United? It looks from their PR history like MNKD has a string of historical announced deals that have just quietly faded into the wind without mention? No details on the milestones were released.
|
|
|
Post by mango on Feb 8, 2019 22:45:40 GMT -5
Sounds like a rather significant event occured that gave a green light in Receptor's development roadmap.
Maybe they will disclose their pipeline soon.
Any chance MannKind is waiting to release their's at the same time as Receptor?
|
|
|
Post by nylefty on Feb 8, 2019 23:20:07 GMT -5
Is kevinmik still around? He was the yahoo doctor who was all over the place, right? Kevin isn't a doctor. He has said he's "in the medical field."
|
|